{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+B&page=32",
    "query": {
      "intervention": "Placebo Comparator B",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 2823,
    "total_pages": 283,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+B&page=33&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+B&page=31&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T10:57:09.011Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06032546",
      "title": "A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Immuno-deficiency Virus (HIV) Disease"
      ],
      "interventions": [
        {
          "name": "Budigalimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Budigalimab",
          "type": "DRUG"
        },
        {
          "name": "ABBV-382",
          "type": "DRUG"
        },
        {
          "name": "Placebo for ABBV-382",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 163,
      "start_date": "2023-10-12",
      "completion_date": "2025-09-22",
      "has_results": true,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-19T10:57:09.011Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06032546"
    },
    {
      "nct_id": "NCT01824823",
      "title": "Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "afatinib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2014-06-30",
      "completion_date": "2020-12",
      "has_results": true,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-11-19T10:57:09.011Z",
      "location_count": 272,
      "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • Fort Collins, Colorado + 186 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01824823"
    },
    {
      "nct_id": "NCT04886154",
      "title": "A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Infections, Meningococcal"
      ],
      "interventions": [
        {
          "name": "MenABCWY-2Gen low dose vaccine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MenABCWY-2Gen high dose vaccine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MenB vaccine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MenACWY vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "10 Years to 50 Years"
      },
      "enrollment_count": 1440,
      "start_date": "2021-06-14",
      "completion_date": "2024-02-02",
      "has_results": true,
      "last_update_posted_date": "2025-05-31",
      "last_synced_at": "2026-11-19T10:57:09.011Z",
      "location_count": 12,
      "location_summary": "Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Longmont",
          "state": "Colorado"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04886154"
    },
    {
      "nct_id": "NCT03334851",
      "title": "Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "PF-06835375",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 74,
      "start_date": "2017-11-17",
      "completion_date": "2022-02-15",
      "has_results": true,
      "last_update_posted_date": "2023-10-30",
      "last_synced_at": "2026-11-19T10:57:09.011Z",
      "location_count": 17,
      "location_summary": "Anniston, Alabama • Beverly Hills, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03334851"
    },
    {
      "nct_id": "NCT01743131",
      "title": "Abatacept as GVHD Prophylaxis Phase 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft vs Host Disease",
        "Malignancy"
      ],
      "interventions": [
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2013-02-01",
      "completion_date": "2024-03-30",
      "has_results": true,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-11-19T10:57:09.011Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Oakland, California • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01743131"
    },
    {
      "nct_id": "NCT01479296",
      "title": "Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5 env A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5 env B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5 env C",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5 gag-pol",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 90,
      "start_date": "2011-12",
      "completion_date": "2017-11-27",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-11-19T10:57:09.011Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01479296"
    },
    {
      "nct_id": "NCT01514357",
      "title": "Nesiritide in Resistant Hypertension",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Nesiritide (BNP)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John C Burnett",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 12,
      "start_date": "2012-04",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2018-03-23",
      "last_synced_at": "2026-11-19T10:57:09.011Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01514357"
    },
    {
      "nct_id": "NCT05606757",
      "title": "A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ventral Hernia",
        "Abdominal Hernia"
      ],
      "interventions": [
        {
          "name": "BOTOX Dose A",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BOTOX",
          "type": "DRUG"
        },
        {
          "name": "BOTOX Dose B",
          "type": "DRUG"
        },
        {
          "name": "BOTOX Dose C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-05-07",
      "completion_date": "2025-09-26",
      "has_results": false,
      "last_update_posted_date": "2024-05-16",
      "last_synced_at": "2026-11-19T10:57:09.011Z",
      "location_count": 2,
      "location_summary": "Mineola, New York • Charlotte, North Carolina",
      "locations": [
        {
          "city": "Mineola",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05606757"
    },
    {
      "nct_id": "NCT05953480",
      "title": "A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Redasemtide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 680,
      "start_date": "2023-07-14",
      "completion_date": "2026-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-11-19T10:57:09.011Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Sarasota, Florida • Augusta, Georgia + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Rockford",
          "state": "Illinois"
        },
        {
          "city": "Munster",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05953480"
    },
    {
      "nct_id": "NCT00401245",
      "title": "The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vasomotor Symptoms"
      ],
      "interventions": [
        {
          "name": "desvenlafaxine succinate sustained release",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 500,
      "start_date": "2006-12",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2011-10-26",
      "last_synced_at": "2026-11-19T10:57:09.011Z",
      "location_count": 55,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Encinitas, California + 44 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Foothill Ranch",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00401245"
    }
  ]
}